White Paper
April 4, 2025

Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Recent technological advancements like antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have improved HER3’s targetability and pharmacological potential.

Functional cookies are required to display this PDF. Update your cookie preferences to view it, or download the PDF directly.

expert

About the author

Headshot of Domenique Catalano.

Domenique Catalano

Senior Manager

View profile

Get in touch

Have a question or need more detail? Tell us what you’re looking for, and our team will be in touch shortly.

Choose a time to talk

専門家との相談日時を選択

Calendar requires cookies. Enable cookies

カレンダーの表示にはCookieの有効化が必要です Cookieを有効にする

Or send us a message and we'll be in touch

面談の有無がお決まりでない場合は、お問い合わせ内容をお送りください。担当者よりご連絡いたします。